Hostname: page-component-7bb8b95d7b-w7rtg Total loading time: 0 Render date: 2024-09-12T14:10:26.980Z Has data issue: false hasContentIssue false
  • English
  • Français

Recommendations for the Management of Behavioral and Psychological Symptoms of Dementia

Published online by Cambridge University Press:  02 December 2014

Nathan Herrmann
Nathan Herrmann*
Affiliation:
Division of Geriatric Psychiatry, University of Toronto, and Sunnybrook & Women’s College Health Sciences Centre, North York, ON
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The behavioral and psychological symptoms of dementia (BPSD) are common, serious problems that impair the quality of life for both patient and caregiver. In order to provide recommendations based upon the best available evidence, a qualitative literature review was performed.

Methods:

A search of the English language medical literature published between 1966 and 2000 was performed. The quality of the studies was assessed by considering the subjects, trial design, analysis and results. Final recommendations were based upon the quality of available evidence.

Results:

The management of BPSD begins with a thorough assessment to search for underlying causes of behaviour change. Concomitant medical illness should be treated and sensory impairment ameliorated. Nonpharmacological approaches should be instituted prior to medication use. These interventions include music, light, changes in level of stimulation and specific behavioral techniques. Antipsychotics are the best studied pharmacological intervention for agitation and aggression and have demonstrated modest but consistent efficacy. Antidepressants such as trazodone and selective serotonin re-uptake inhibitors, as well as anticonvulsants such as carbamazepine and valproic acid have also demonstrated efficacy. Benzodiazepines can be used for short-term treatment as p.r.n. agents when necessary. Pharmacotherapy must be monitored closely for both effectiveness and side effects, with consideration of medication withdrawal when appropriate.

Conclusion:

The management of BPSD can significantly improve the quality of life for the patient and caregiver. Their assessment and management are essential components of the treatment of dementia.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 28 , Supplement S1: Canadian Consensus Conference on Dementia , May 2001 , pp. S96 - S107
Copyright
Copyright © The Canadian Journal of Neurological 2001

References

1. Finkel, SI (ed). Behavioral and psychological signs and symptomsof dementia. Implications for research and treatment. Int Psychogeriatr 1996; 8(suppl 3).Google Scholar
2. American Psychiatric Association: Diagnostic and statisticalmanual of mental disorders. 4th Ed. Washington (DC): 3American Psychiatric Association; 1994.Google Scholar
3. NINCDS-ADRDA Work Group. Criteria for the clinical diagnosisof Alzheimer’s disease. J Am Geriatr Soc 1985; 33:2–3.Google Scholar
4. Tonkonongy, J, Moak, GS. Alois Alzheimer on presenile dementia. J Geriatr Psychiatry Neurol 1988; 2:199–206.CrossRefGoogle Scholar
5. Rabins, PV, Mace, NL, Lucas, MJ. The impact of dementia on thefamily. JAMA 1982; 248:333–335.Google Scholar
6. Teri, L, Rabins, P, Whitehouse, P, et al. Management of behaviourdisturbance in Alzheimer’s disease: current knowledge and future direction. Alzheimer Dis Assoc Disord 1992; 6(2):77–88.Google Scholar
7. Rabins, PV, Folstein, MF. Delirium and dementia. Diagnosticcriteria and fatality rates. Br J Psychiatry 1982; 140:194–253.Google Scholar
8. Reisberg, B, Borenstein, J, Salob, SP, et al. Behavioral symptoms inAlzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987; 48 Suppl. 5:9–15.Google ScholarPubMed
9. Merriam, AE, Aronson, MK, Gaston, P. The psychiatric symptoms ofAlzheimer’s disease. J Am Geriatr Soc 1988; 36:7–12.CrossRefGoogle Scholar
10. Teri, L, Larson, EB, Reifler, BV. Behavioral disturbance in dementiaof the Alzheimer’s type. J Am Geriatr Soc 1988; 36:1–6.Google Scholar
11. Wragg, RE, Jeste, DV. Overview of depression and psychosis inAlzheimer’s disease. Am J Psychiatry 1989; 146(5):577–587.Google ScholarPubMed
12. Reisberg, B, Ferris, SH, de Leon, MJ, et al. Global deterioration scale(GDS). Psychopharmacol Bull 1988; 24:661–663. Google ScholarPubMed
13. Kunik, ME, Yudofsky, SC, Silver, JM, et al. Pharmacologic approachto management of agitation associated with dementia. J Clin Psychiatry 1994; 55(2 Suppl.):13–17.Google Scholar
14. Whall, AL, Gillis, GL, Yankou, D, et al. Disruptive behaviour inelderly nursing home residents: a survey of nursing staff. J Gerontol Nurs 1992; 12:13–17.Google Scholar
15. Zimmer, JG, Watson, N, Treat, A. Behavioral problems amongpatients in skilled nursing facilities. Am J Public Health 1984; 74(10):1118–1121.Google Scholar
16. Swearer, JM, Drachman, DA, O’Donnell, BF, et al. Troublesome anddisruptive behaviours in dementia; relationship to diagnosis anddisease severity. J Am Geriatr Soc 1988; 36(9):784–790.CrossRefGoogle Scholar
17. Sultzer, DL, Levin, HS, Mahler, ME, et al. Assessment of cognitive,psychiatric and behavioral disturbances in patients with dementia: the neurobehavioral rating scale. J Am Geriatr Soc 1992; 40:549–555.Google Scholar
18. Mega, MS, Cummings, JL, Foorello, T, et al. The spectrum ofbehavioral changes in Alzheimer’s disease. Neurology 1996; 46(1):130–135.Google Scholar
19. Burns, A, Jacoby, R, Levy, R. Psychiatric phenomena in Alzheimer’sdisease. I: Disorders of thought content. Br J Psychiatry 1990; 157:72–76.CrossRefGoogle Scholar
20. Burns, A, Jacoby, R, Levy, R. Psychiatric phenomena in Alzheimer’sdisease. II: Disorders of perception. Br J Psychiatry 1990; 157:76–81.Google Scholar
21. Burns, A, Jacoby, R, Levy, R. Psychiatric phenomena in Alzheimer’sdisease. III. Disorders of mood. Br J Psychiatry 1990; 157:81–86.Google Scholar
22. Burns, A, Jacoby, R, Levy, R. Psychiatric phenomena in Alzheimer’sdisease. IV. Disorders of behaviour. Br J Psychiatry 1990; 157:86–94.CrossRefGoogle Scholar
23. Cummings, JL, Miller, B, Hill, MA, Neshkes, R. Neuropsychiatricaspects of multi-infarct dementia and dementia of the Alzheimertype. Arch Neurol 1987; 44:389–393.Google Scholar
24. Brun, A, Englund, B, Gustafson, L, et al. Clinical andneuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57:416–418.Google Scholar
25. McKeith, IG, Galasko, D, Wilcock, GK, Byrne, EJ. Lewy bodydementia – diagnosis and treatment. Br J Psychiatry 1995; 167:709–717.Google Scholar
26. Ryden, MB. Aggressive behaviour in persons with dementia wholive in the community. Alzheimer Dis Assoc Disord 1988; 2(4):342–355.CrossRefGoogle ScholarPubMed
27. Chenoweth, B, Spencer, B. Dementia: the experience of familycaregivers. Gerontologist 1986; 26:267–272.Google Scholar
28. Steele, C, Rovner, B, Chase, GA, et al. Psychiatric symptoms andnursing home placement of patients with Alzheimer’s disease. Am J Psychiatry 1990; 147:1049–1051.Google Scholar
29. Woolf, SH, Battista, RN, Anderson, GM, Longan, AG, Wang, EEL. Assessing the clinical effectiveness of preventative manoeuvres: analytical principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epidemiol 1990; 43:891–905.Google Scholar
30. Patterson, CJS, Gauthier, S, Bergman, H, et al. The recognition,assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Can Med Assoc J 1999; 160(12 Suppl):1–15.Google Scholar
31. Corbin, S, Eastwood, R. Sensory deficits and mental disorders of oldage: causal or coincidental associations? Psychol Med 1986; 16:251–256.Google Scholar
32. Horowitz, A. The relationship between vision impairment and theassessment of disruptive behaviours among nursing home residents. Gerontologist 1997; 37:620–628.Google Scholar
33. Chapman, FM, Dickinson, J, McKeith, I, Ballard, C. Associationamong visual hallucinations, visual acuity and specific eye pathologies in Alzheimer’s disease: treatment implications. Am J Psychiatry 1999; 156:1983–1985.Google Scholar
34. Learoyd, BM. Psychotropic drugs and the elderly patient. Med JAust 1972; 1:1131–1133.Google Scholar
35. American Psychiatric Association. Practice guideline for thetreatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry 1997; 154 (suppl).Google Scholar
36. Weiner, MF, Koss, E, Wild, KV, et al. Measures of psychiatricsymptoms in Alzheimer patients: a review. Alzheimer Dis Assoc Disord 1996; 10(1):20–30.Google ScholarPubMed
37. Folstein, MF, Folstein, SE, McHugh, PR. “Mini-Mental State”: apractical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198.Google Scholar
38. Cummings, JL, Mega, M, Gray, K, et al. The neuropsychiatricinventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44(12):2308–2314.Google Scholar
39. Cohen-Mansfield, J, Billig, N. Agitated behaviours in the elderly. I.A conceptual review. J Am Geriatr Soc 1986; 34:711–721.Google Scholar
40. Cohen-Mansfield, J. Agitated behaviours in the elderly. II.Preliminary results in the cognitively deteriorated. J Am Geriatr Soc 1986; 34:722–727.Google Scholar
41. Nilsson, K, Palmerstierna, T, Wistedt, B. Aggressive behaviour inhospitalized psychogeriatric patients. Acta Psychiatr Scand 1988; 78:172–175.CrossRefGoogle Scholar
42. Palmstierna, T, Wistedt, B. Staff observation aggression scale,SOAS. Presentation and evaluation. Acta Psychiatr Scand 1987; 76:657–663.Google Scholar
43. Beck, CK, Shue, VM. Interventions for treating disruptive behaviourin demented elderly people. Nurs Clin North Am 1994; 29:143–155.Google Scholar
44. Stewart, JT. Management of behaviour problems in the dementedpatient. Am Fam Physician 1995; 52:2311–2317.Google Scholar
45. Burgio, L. Interventions for the behavioral complications ofAlzheimer’s disease: behavioral approaches. Int Psychogeriatrics 1996; 8(Suppl 1):45–52.CrossRefGoogle Scholar
46. Opie, J, Rosewarne, R, O’Connor, DW. The efficacy of psychosocialapproaches to behavior disorders in dementia: a systematicliterature review. Aust NZ J Psychiatry 1999;33:789–799.Google Scholar
47. Bourgeois, MS, Burgio, LD, Schulz, R, et al. Modifying repetitiveverbalizations of community-dwelling patients with A D. Gerontologist 1997;37:30–39.Google Scholar
48. Rovner, BW, Steele, CD, Shuely, Y, Folstein, MF. A randomized trialof dementia care in nursing homes. J Am Geriatr Soc 1996; 44:7–13.Google Scholar
49. Cleary, TA, Clamon, C, Price, M, Shullaw, G. A reduced stimulationunit: effects on patients with Alzheimer’s disease and related disorders. Gerontologist 1988; 28:511–514.Google Scholar
50. Karlsson, I, Brane, G, Melin, E, Nyth, AL, Rybo, E. Effects ofenvironmental stimulation on biochemical and psychological variables in dementia. Acta Psychiatr Scand 1988; 77:207–213.CrossRefGoogle Scholar
51. Casby, JA, Holm, MB. The effect of music on repetitive disruptivevocalizations of persons with dementia. Am J Occup Ther 1994; 48:883–889.Google Scholar
52. Gerdner, L, Swanson, L. Effects of individualized music onconfused and agitated elderly patients. Arch Psychiatr Nurs 1993; 5:284–291.Google Scholar
53. Goddaer, J, Abraham, IL. Effects of relaxing music on agitationduring meals among nursing home residents with severe cognitive impairment. Arch Psychiatr Nurs 1994; 8:150–158.Google Scholar
54. Ragneskog, H, Kihlgren, M, Karlsson, I, Norberg, A. Dinner musicfor demented patients: analysis of video-recorded observations. Clin Nurs Res 1996; 5:262–277.Google Scholar
55. Burgio, L, Scilley, K, Hardin, JM, Hsu, C, Yancey, J. Environmental “white noise”: an intervention for verbally agitated nursing home residents. J Gerontol 1996; 51B:364–373.Google Scholar
56. Satlin, A, Volicer, L, Ross, V, Herz, L, Campbell, S. Bright lighttreatment of behavioral and sleep disturbances in patients with Alzheimer’s disease. Am J Psychiatry 1992; 149:1028–1032.Google ScholarPubMed
57. Van Someren, EJW, Kessler, A, Mirmiran, M, Swaab, DF. Indirectbright light improves circadian rest-activity rhythm disturbances in demented patients. Biol Psychiatry 1997; 41:955–963.Google Scholar
58. Lyketsos, CG, Veiel, LL, Baker, A, Steele, C. A randomized,controlled trial of bright light therapy for agitated behaviors in dementia patients residing in long-term care. Int J Geriatr Psychiatry 1999;14:520–525.Google Scholar
59. Rapp, MS, Flint, AJ, Herrmann, N, et al. Behavioral disturbances indemented elderly people. Can J Psychiatry 1992; 37:651–657.Google Scholar
60. Vacarro, FJ. Application of operant procedures in a group ofinstitutionalized aggressive geriatric patients. Psychol Aging 1988; 3:22–28. Google Scholar
61. Boehm, S, Whall, AL, Cosgrove, KL, Locke, JD, Schlenk, EA. Behavioral analyses and nursing interventions for reducing disruptive behaviors of patients with dementia. Appl Nurs Res 1995; 8:118–122.CrossRefGoogle Scholar
62. Radebaugh, TS, Buckholtz, N, Khachaturian, Z (eds). Behavioralapproaches to the treatment of Alzheimer’s disease: research strategies. Int Psychogeriatr 1996; 8(Suppl 1).CrossRefGoogle Scholar
63. Herrmann, N, Lanctôt, K, Naranjo, C. Behavioural disorders indemented elderly patients: current issues in pharmacotherapy.CNS Drugs 1996; 6(4):280–300.Google Scholar
64. Herrmann, N, Lanctôt, KL. From transmitters to treatment: thepharmacotherapy of behavioural disturbances in dementia. Can J Psychiatry 1997; 42(suppl 1):51S–64S.Google Scholar
65. Avorn, J, Dreyer, P, Connelly, K, et al. Use of psychoactivemedication and the quality of care in rest homes: findings and policy implications of a state-wide study. N Engl J Med 1989; 320:227–232.CrossRefGoogle Scholar
66. Hesse, K, Driscoll, A, Jacobson, S. Neuroleptic prescriptions foracutely ill geriatric patients. Arch Intern Med 1993; 153:2581–2587.Google Scholar
67. Gurwitz, JH, Sourerai, SB, Avorn, J. Improving medicationprescribing and utilization in the nursing home. J Am Geriatr Soc 1990; 38:442–452.Google Scholar
68. Lantz, MS, Louis, A, Lowenstein, G, et al. A longitudinal study ofpsychotropic prescriptions in a teaching nursing home. Am J Psychiatry 1990; 137:1637–1639.Google Scholar
69. Ryden, MB. Aggressive behaviour in persons with dementia wholive in the community. Alzheimer Dis Assoc Disord 1988; 2:342–355.Google Scholar
70. Semla, TP, Palla, K, Poddig, B, et al. Effect of the OmnibusReconciliation Act 1987 on antipsychotic prescribing in nursing home residents. J Am Geriatr Soc 1994; 42:648–652.CrossRefGoogle ScholarPubMed
71. Beers, MH, Ouslander, JG, Rollingher, I, et al. Explicit criteria fordetermining inappropriate medication use in nursing home residents. Arch Intern Med 1991; 151:1825–1832.Google Scholar
72. Naranjo, CA, Herrmann, N, Mittmann, N, et al. Recent advances ingeriatric psychopharmacology. Drugs Aging 1995; 7:184–202.Google Scholar
73. Sunderland, T, Tariot, PN, Cohen, RM, et al. Anticholinergicsensitivity in patients with dementia of the Alzheimer type and aged-matched controls. Arch Gen Psychiatry 1987; 44:418–426.Google Scholar
74. Lipowski, ZJ. Delirium in the elderly patient. N Eng J Med 1989; 320:578–582.Google ScholarPubMed
75. Barton, R, Hurst, L. Unnecessary use of tranquilizers in elderlypatients. Br J Psychiatry 1966; 112:989–990.Google Scholar
76. Raskind, MA, Risse, SC, Lampe, TH. Dementia and antipsychoticdrugs. J Clin Psychiatry 1987; 48(suppl):16–18.Google Scholar
77. Risse, SC, Cubberly, L, Lampe, TH, Zemmers, R, Raskind, MA. Acute effects of neuroleptic withdrawal in elderly dementia patients. J Geriatr Drug Therapy 1987; 2:65–77.Google Scholar
78. Ray, WA, Taylor, JA, Meador, KG, et al. Reducing antipsychoticdrug use in nursing homes. A controlled trial of providereducation. Arch Int Med 1993; 153:713–721.CrossRefGoogle Scholar
79. Purushotam, BT, Meador, KG, Gideon, P, Fought, RL, Ray, WE. Effects of antipsychotic withdrawal in elderly nursing homeresidents. J Am Geriatr Soc 1994; 42:280–286.Google Scholar
80. Horwitz, GJ, Tariot, PN, Mead, K, Cox, C. Discontinuation ofantipsychotics in nursing home patients with dementia. Am JGeriatr Psychiatry 1995; 3:290–299.Google Scholar
81. Salzman, C, Fisher, J, Nobel, K, et al. Cognitive improvementfollowing benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry 1992; 7:89–93.Google Scholar
82. Devanand, DP, Jacobs, DM, Tang, MX, et al. The course ofpsychopathologic features in mild to moderate Alzheimer’s disease. Arch Gen Psychiatry 1997;54:257–263.Google Scholar
83. Yeager, BF, Farnett, LE, Ruzicka, SA. Management of the behavioralmanifestations of dementia. Arch Intern Med 1995; 155:250–260.Google Scholar
84. Peisah, C, Brodaty, H. Practical guidelines for the treatment ofbehavioral complications of dementia. Med J Aust 1994; 161:558–563.Google Scholar
85. Yudofsky, SC, Silver, JM, Hales, RE. Pharmacologic management ofaggression in the elderly. J Clin Psychiatry 1990; 51(20Suppl):22S–28S.Google Scholar
86. Lanctôt, KL, Best, TS, Mittmann, N, et al. Efficacy and safety ofneuroleptics in behavioral disorders associated with dementia. JClin Psychiatry 1998;59:550–561.Google Scholar
87. Devanand, DP, Marden, K, Michaels, KS, et al. A randomized,placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer’s disease. Am J Psychiatry 1998;155:1512–1520.Google Scholar
88. Sweet, RA, Mulsant, BH, Pollock, BG, et al. Neuroleptic-inducedparkinsonism in elderly patients diagnosed with psychotic major depression and dementia of the Alzheimer type. Am J Geriatr Psychiatry 1996; 4:311–319.CrossRefGoogle ScholarPubMed
89. McShane, R, Keene, J, Gedling, K, et al. Do neuroleptic drugs hastencognitive decline in dementia? Prospective study with necropsy follow up. Br Med J 1997; 314:266–270.Google Scholar
90. McKeith, I, Fairbairn, A, Perry, R et al. Neuroleptic sensitivity inpatients with senile dementia of Lewy body type. Br Med J 1992;305:673–678.Google Scholar
91. Oberholzer, AF, Hendriksen, C, Monsch, AU, et al. Safety andeffectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992; 4:187–195.CrossRefGoogle Scholar
92. Pitner, JK, Mintzer, JE, Pennypacker, LC, et al. Efficacy and adverseeffects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995; 56:180–185.Google Scholar
93. Salzman, C, Vaccaro, B, Lieff, J, et al. Clozapine in older patientswith psychosis and behavioral disruption. Am J GeriatrPsychiatry 1995; 3:26–33.Google Scholar
94. Walker, Z, Grace, J, Overshot, R, et al. Olanzapine in dementia withLewy bodies: a clinical study. Int J Geriatr Psychiatry 1999;14:459–466.Google Scholar
95. Solomons, K, Geiger, O. Olanzapine use in the elderly: aretrospective analysis. Can J Psychiatry 2000;45:151–155.Google Scholar
96. Bymaster, FP, Calligaro, DO, Falcone, , et al. Radioreceptor bindingprofile of atypical antipsychotic olanzapine. Neuropsycho-pharmacology 1996;14:87–96.Google Scholar
97. Street, J, Clark, S, Gannon, KS, et al. Olanzapine treatment ofpsychotic and behavioural symptoms in patients with Alzheimer’s disease in nursing care facilities:a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000;57:968–967.CrossRefGoogle ScholarPubMed
98. Schneider, L, Arvantis, L, Sweitzer, D. Quetiapine may reducehostility in patients with psychosis related to Alzheimer’s disease. Am J Geriatr Psychiatry 1999; 7(Suppl):58.Google Scholar
99. Madhusoodanan, S, Brenner, R, Araujo, L, et al. Efficacy ofrisperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995;56:514–518.Google Scholar
100. Zarate, CA, Baldessarini, RJ, Siegel, AJ, et al. Risperidone in theelderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997; 58:311–317.Google Scholar
101. Goldberg, RJ, Goldberg, J. Risperidone for dementia-relateddisturbed behaviour in nursing home residents: a clinical experience. Int Psychogeriatr 1997; 9:65–68.Google Scholar
102. Herrmann, N, Rivard, MF, Flynn, M, et al. Risperidone for thetreatment of behavioral disturbances in dementia. J Neuropsychiatry Clin Neurosci, in press.Google Scholar
103. Katz, IR, Jeste, DV, Mintzer, JE, et al. Comparison of risperidone andplacebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107–115.Google Scholar
104. De Deyn, PP, Rabheru, K, Rasmussen, A, et al. A randomized trial ofrisperidone, placebo and haloperidol for behavioral symptoms ofdementia. Neurology 1999; 53:946–955.Google Scholar
105. Jeste, DV, Lacro, JP, Bailey, A, et al. Lower incidence of tardivedyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716–719.Google Scholar
106. Latimer, PR. Tardive dyskinesia: a review. Can J Psychiatry 1995; 40(2 suppl):49–54.Google Scholar
107. Schneider, LS, Sobin, PB. Nonneuroleptic medications in themanagement of agitation in Alzheimer’s disease and other dementia: a selective review. Int J Geriatr Psychiatry 1991; 6:691–708.Google Scholar
108. Aisen, PS, Johannessen, JD, Marin, DB. Trazodone for behavioraldisturbances in Alzheimer’s disease. Am J Geriatr Psychiatry 1993; 2:349–350.CrossRefGoogle Scholar
109. Houlihan, DJ, Mulsant, BH, Sweet, RA, et al. A naturalistic study oftrazodone in the treatment of behavioral complications of dementia. Am J Geriatr Psychiatry 1994; 2:78–85.CrossRefGoogle ScholarPubMed
110. Lebert, F, Pasquier, F, Petit, H. Behavioral effects of trazodone inAlzheimer’s disease. J Clin Psychiatry 1994; 55:536–538.Google Scholar
111. Tejera, CA, Saravoy, SM. Treatment of organic personalitysyndrome with low-dose trazodone. J Clin Psychiatry 1995; 56:374–375.Google Scholar
112. Lawlor, BA, Radcliffe, J, Molchan, SE, et al. A pilot placebo-controlled study of trazodone and buspirone in Alzheimer’s disease. Int J Geriatr Psychiatry 1994; 9:55–59.Google Scholar
113. Sultzer, DL, Gray, KF, Gunay, I, Berisford, MA, Mahler, ME. Adouble-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J GeriatrPsychiatry 1997; 5:60–69.Google Scholar
114. Karlsson, I. Pharmacologic treatment of noncognitive symptoms ofdementia. Acta Neurol Scand 1996; Suppl 165:101–104.Google Scholar
115. Lebert, F, Pasquier, F, Petit, H. Behavioral effects of fluoxetine indementia of Alzheimer’s type. Int J Geriatr Psychiatry 1994; 9:590–591.Google Scholar
116. Geldmacher, DS, Waldman, AJ, Doty, L, et al. Fluoxetine indementia of the Alzheimer’s type: prominent adverse effects and failure to improve cognition (letter). J Clin Psychiatry 1994; 55:161.Google Scholar
117. Burke, WJ, Dewan, V, Wengel, SP, et al. The use of selective serotoninreuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatr Psychiatry 1997; 12:519–625.Google Scholar
118. Olafsson, K, Jorgensen, S, Jensen, HV, et al. Fluvoxamine in thetreatment of demented elderly patients: a double-blind placebo-controlled study. Acta Psychiatr Scand 1992; 851:453–456.Google Scholar
119. Nyth, AL, Gottfries, CG. The clinical efficacy of citalopram intreatment of emotional disturbances in dementia disorders: aNordic multicentre study. Br J Psychiatry 1990; 157:894–901.Google Scholar
120. Pollock, BG, Mulsant, BH, Sweet, R, et al. An open pilot study ofcitalopram for behavioral disturbances of dementia. Am J GeriatrPsychiatry 1997; 5:70–78.Google Scholar
121. Swartz, JR, Miller, BL, Lesser, IM, Darby, AL. Frontotemporaldementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58:212–216.Google Scholar
122. Martini, E, Pataky, I, Szelagy, K, et al. Brief information on an earlyphase II study with deprenyl in demented patients. Pharmacopsychiatry 1987; 20:256–257.Google Scholar
123. Schneider, LS, Gleason, R, Zemansky, MF, et al. A pilot study oflow-dose l-deprenyl in Alzheimer’s disease. J Geriatr PsychiatryNeurol 1991; 4:143–148.Google Scholar
124. Goad, DL, Davis, CM, Liem, P, et al. The use of selegiline inAlzheimer’s patients with behaviour problems. J Clin Psychiatry 1991; 52:342–345.Google Scholar
125. Tariot, PN, Cohen, RM, Sunderland, T, et al. l-Deprenyl inAlzheimer’s disease: preliminary evidence for behavioral change with monoamine oxidase B inhibition. Arch Gen Psychiatry 1987; 44:427–433.Google Scholar
126. Mangoni, A, Grassi, MP, Frattola, L, et al. Effects of a MAO-Binhibitor in the treatment of Alzheimer’s disease. Eur Neurol 1991; 31:100–107.Google Scholar
127. Burke, WJ, Roccaforte, WH, Wengel, SP, et al. l-Deprenyl in thetreatment of mild dementia of the Alzheimer type: results of a 15-month trial. J Am Geriatr Soc 1993; 41:1219–1225.Google Scholar
128. Freedman, M, Rewilak, D, Xerri, T, et al. L-deprenyl in Alzheimer’sdisease: cognitive and behavioral effects. Neurology 1998; 50: 660–668.Google Scholar
129. Gleason, RP, Schneider, LS. Carbamazepine treatment of agitationin Alzheimer’s outpatients refractory to neuroleptics. J Clin Psychiatry 1990; 51:115–118.Google Scholar
130. Leibovici, A, Tariot, PN. Carbamazepine treatment of agitationassociated with dementia. J Geriatr Psychiatry Neurol 1988; 1:110–112.Google Scholar
131. Patterson, JF. Carbamazepine for assaultive patients with organicbrain disease. Psychosomatics 1987; 28:579–581.CrossRefGoogle Scholar
132. Patterson, JF. A preliminary study of carbamazepine in thetreatment of patients with dementia. J Geriatr Psychiatry Neurol 1988; 1:21–23.Google Scholar
133. Lemke, MR. Effects of carbamazepine on agitation in Alzheimer’sinpatients refractory to neuroleptics. J Clin Psychiatry 1995; 56:354–357.Google Scholar
134. Chambers, CA, Bain, J, Rosebottom, R, et al. Carbamazepine insenile dementia and overactivity - a placebo controlled double blind trial. International Research Communication System, Medical Sciences 1982; 10:505–506.Google Scholar
135. Tariot, PN, Erb, R, Leibovici, A, et al. Carbamazepine treatment ofagitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc 1994; 42:1160–1166.Google Scholar
136. Cooney, C, Mortimer, A, Smith, A, et al. Carbamazepine use inaggressive behaviour associated with senile dementia. Int J Geriatr Psychiatry 1996; 11:901–905.Google Scholar
137. Tariot, PN, Erb, R, Podgorski, CA, et al. Efficacy and tolerability ofcarbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998;155:54–61.Google Scholar
138. Mellow, AM, Solano-Lopez, C, Davis, S. Sodium valproate in thetreatment of behavioral disturbance in dementia. J GeriatrPsychiatry Neurol 1993; 6:205–209.Google Scholar
139. Sandborn, WD, Bendfeldt, F, Hamdy, R. Valproic acid for physicallyaggressive behaviour in geriatric patients. Am J GeriatrPsychiatry 1995; 3:239–242.Google Scholar
140. Sival, RC, Haffmans, PMJ, Van Gent, PP, et al. The effects of sodiumvalproate on disturbed behaviour in dementia. J Am Geriatr Soc 1994; 42:906–909.Google Scholar
141. Mazure, CM, Druss, BG, Cellar, JS. Valproate treatment of olderpsychotic patients with organic mental syndromes and behavioral dyscontrol. J Am Geriatr Soc 1992;40:914–916.Google Scholar
142. Narayan, M, Nelson, JC. Treatment of dementia with behavioraldisturbance using divalproex or a combination of divalproex and a neuroleptic. J Clin Psychiatry 1997; 58:351–354.Google Scholar
143. Herrmann, N. Valproic acid treatment of agitation in dementia. CanJ Psychiatry 1998; 43:69–72.Google Scholar
144. Regan, WM, Gordon, SM. Gabapentin for behavioral agitation inAlzheimer’s disease. J Clin Psychopharmacol 1997; 17:59–60.Google Scholar
145. Sheldon, LJ, Ancill, RJ, Holliday, SG. Gabapentin in geriatricpsychiatry patients. Can J Psychiatry 1998;43:422–423.Google Scholar
146. Goldenberg, G, Kahaner, K, Basavaraju, N et al. Gabapentin fordisruptive behavior in an elderly demented patient. Drugs Aging 1998;13:183–184.Google Scholar
147. Low, RA, Brandes, M. Gabapentin for the management of agitation. J Clin Psychopharmacol 1999;19:482–483.Google Scholar
148. Roane, DM, Feinberg, TE, Mecler, L, et al. Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry ClinNeurosci 2000;12:40–43.Google Scholar
149. Herrmann, N, Lanctôt, KL, Myszak, M. Effectiveness of gabapentinfor the treatment of behavioral disorders in dementia. J ClinPsychopharmacol 2000; 20:90–93.Google Scholar
150. Alexapoulos, GS, Silver, JM, Kahn, DA, et al(eds). Treatment ofagitation in older persons with dementia: the expert consensus guideline series. Postgrad Med 1998;26.Google Scholar
151. Petri, WM, Ban, TA. Propranolol in organic agitation (letter). Lancet 1981; 1:324.Google Scholar
152. Greendyke, RM, Schuster, DB, Wooton, JA. Propranolol in thetreatment of assaultive patients with organic brain disease. J ClinPsychopharmacol 1984; 4:282–285.Google Scholar
153. Greendyke, RM, Kanter, DR, Schuster, DB, et al. Propranololtreatment of assaultive patients with organic brain disease. J Nerv Ment Dis 1986; 174:290–294.Google Scholar
154. Greendyke, RM, Kanter, DR. Therapeutic effects of pindolol onbehavioral disturbances associated with organic brain disease: adouble-blind study. J Clin Psychiatry 1986; 47:423–426.Google Scholar
155. Greendyke, RM, Berner, JP, Webster, JC, et al. Treatment ofbehavioral problems with pindolol. Psychosomatics 1989; 30:161–165.Google Scholar
156. Weiler, PG, Mugas, D, Bernick, C. Propranolol for the control ofdisruptive behaviour in senile dementia. J Geriatr Psychiatry Neurol 1988; 226–230.Google Scholar
157. Smith, DA, Perry, PJ. Non-neuroleptic treatment of disruptive behviour in organic mental syndromes. Ann Pharmcother 1992; 26:1400–1408.Google Scholar
158. Shankle, WR, Nielson, KA, Cotman, CW. Low-dose propranololreduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. AlzheimerDis Assoc Disord 1995; 4:233–237.Google Scholar
159. Beber, CR. Management of behaviour in the institutionalized aged. Dis Nerv Sys 1965; 26:591–595.Google Scholar
160. Chesrow, EJ, Kaplitz, SE, Vetra , H, et al. Blind study of oxazepam inthe management of geriatric patients with behavioral problems. Clin Med 1965; 71:1001–1005.Google Scholar
161. Sanders, JF. Evaluation of oxazepam and placebo in emotionallydisturbed aged patients. Geriatrics 1965; 20:739–746.Google Scholar
162. Kirven, LE, Montero, EF. Comparison of thioridazine and diazepamin the control of nonpsychotic symptoms associated with senility: double-blind study. J Am Geriatr Soc 1973; 21:546–551.Google Scholar
163. Covington, JS. Alleviating agitation, apprehension and relatedsymptoms in geriatric patients: a double-blind comparison of phenothiazine and a benzodiazepine. South Med J 1975; 68:719–724.Google Scholar
164. Stotskey, B. Multicenter study comparing thioidazine withdiazepam and placebo in elderly nonpsychotic patients with emotional and behavioral disorders. Clin Ther 1984; 6:546–549.Google Scholar
165. Coccaro, EF, Kramer, E, Zemishlany, Z, et al. Pharmacologictreatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990; 147:1640–1645.Google Scholar
166. Stern, RG, Duffelmeyer, ME, Zemeshlani, Z, et al. The use ofbenzodiazepines in the management of behavioral symptoms indemented patients. Psychiatr Clin North Am 1991; 14:375–384.Google Scholar
167. Frinhar, JP, Alvarez, WA. Clonazepam treatment of organic brainsyndromes in three elderly patients. J Clin Psychiatry 1986; 47:525–526.Google Scholar
168. Smeraski, PJ. Clonazepam treatment of multi-infarct dementia. JGeriatr Psychiatry Neurol 1988; 1:47–48.Google Scholar
169. Ginsburg, ML. Clonazepam for agitated patients with Alzheimer’sdisease (letter). Can J Psychiatry 1991; 36:237–238.Google Scholar
170. Colenda, CC. Buspirone in treatment of agitated demented patient(letter). Lancet 1988; 2:11–69.Google Scholar
171. Herrmann, N, Eryavec, G. Buspirone in the management of agitationand aggression associated withdementia. AmJ GeriatrPsychiatry 1993; 1:249–253.Google Scholar
172. Sakauye, KM, Camp, CJ, Ford, PA. Effects of buspirone on agitationassociated with dementia. Am J Geriatr Psychiatry 1993; 1:82–84.Google Scholar
173. Levy, MA, Burgio, LD, Sweet, R, et al. A trial of buspirone for thecontrol of disruptive behaviours in community dwelling patients with dementia. Int J Geriatr Psychiatry 1994; 841; 848.Google Scholar
174. Cantillon, M, Brunswick, R, Molina, D, et al. Buspirone vshaloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer’s disease. Am J Geriatr Psychiatry 1996; 4:263–267.Google Scholar
175. Cummings, JL. Cholinesteraseinhibitors: a newclass ofpsychotropic compounds. Am J Psychiatry 2000;157:4–15.Google Scholar
176. Farlow, M, Gracon, SI, Hershey, LA, et al. A controlled trial oftacrine in Alzheimer’s disease. JAMA 1992; 268:2523–2529.Google Scholar
177. Davis, KL, Thal, LJ, Gamzu, ER, et al. A double-blind placebocontrolled multicentre study of tacrine for Alzheimer’s disease. N Engl J Med 1992; 327:1253–1259.Google Scholar
178. Knapp, MJ, Knopman, DS, Solomon, PR, et al. A 3 0 – w e e krandomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271:985–991.Google Scholar
179. Kaufer, DI, Cummings, JL, Christine, D. Effect of tacrine onbehavioral symptoms in Alzheimer’s disease: an open-label study. J Geriatr Psychiatry Neurol 1996; 9:1–6.Google Scholar
180. Cummings, JL, Gorman, DG, Shapiro, J. Physostigmine amelioratesthe delusions of Alzheimer’s disease. Biol Psychiatry 1993; 33:536–541.Google Scholar
181. Bodick, NC, Offen, WW, Levey, AI, et al. Effects of xanomeline, aselective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer’s disease. Arch Neurol 1997; 54:465–473.Google Scholar
182. Mega, MS, Masterman, DM, O’Connor, SM, et al. The spectrum ofbehavioral responses to cholinesterase inhibitor therapy in Alzheimer’s disease. Arch Neurol 1999;56:1388–1393.Google Scholar
183. Cummings, JL, Donohue, JA, Brooks, RL. The relationship betweendonepezil and behavioral disturbances in patients with Alzheimer’s disease. Am J Geriatr Psychiatry 2000;8:134–140.Google Scholar
184. Lanctôt, KL, Herrmann, N. Donepezil for behavioral disordersassociated with Lewy bodies: a case series. Int J Geriatr Psychiatry 2000;15:338–345.Google Scholar
185. Shea, C, MacKnight, C, Rockwood, K. Donepezil for treatment ofdementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998;10:229–238.Google Scholar
186. Morris, JC, Cyrus, PA, Orazem, J, et al. Metrifonate benefitscognitive, behavioral and global function in patients with Alzheimer’s disease. Neurology 1998;50:1222–1230.CrossRefGoogle ScholarPubMed
187. Cooper, AJ. Medroxyprogestrone acetate (MPA) treatment ofsexual acting out in men suffering from dementia. J ClinPsychiatry 1987; 48:368–370.Google Scholar
188. Kyomen, HH, Nobel, KW, Wei, JY. The use of oestrogen to decreaseaggressive physical behaviour in elderly men with dementia. J Am Geriatr Soc 1991; 39:1110–1112.Google Scholar
189. Nadal, M, Allgulander, S. Normalization of sexual behaviour in afemale with dementia after treatment with cyproterone. Int JGeriatr Psychiatry 1993; 8:265–267.Google Scholar
190. Rich, SS, Ovseiw, F. Leuprolide acetate for exhibitionism inHuntington’s disease. Mov Disord 1994; 9:353–357.Google Scholar
191. Ott, BR. Leuprolide treatment of sexual aggression in a patient withdementia and the kluver-bucy syndrome. Clin Neuropharmacol 1995; 18:443–447.Google Scholar
192. Kyomen, HH, Satlin, A, Hennen, J, et al. Estrogen therapy andaggressive behavior in elderly patients with moderate-to-severedementia. Am J Geriatr Psychiatry 1999;7:339–348.Google Scholar
193. Zoldan, J, Friedberg, G, Goldberg-Stern, H, et al. Ondansetron forhallucinosis in advanced Parkinson’s disease. Lancet 1993; 341:562–563.Google Scholar
194. Zoldan, J, Griedberg, G, Lioneh, M, et al. Psychosis in advancedParkinson’s disease: treatment with ondansetron, a 5HT3 receptor antagonist. Neurology 1995; 45:1305–1308.Google Scholar
195. Volicer, L, Stelly, M, Morris, J, McLaughlin, J, Volicer, BJ. Effects ofdronabinol on anorexia and disturbed behaviour in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 1997; 12:913–919.Google Scholar
196. Carlyle, W, Killick, L, Ancill, R. ECT: an effective treatment in thescreaming demented patient. J Am Geriatr Soc 1991; 39:637.Google Scholar
197. Holmberg, SK, Tariot, PN, Challapalli, R. Efficacy of ECT foragitation in dementia. Am J Geriatr Psychiatry 1996; 4:330–334 .Google Scholar